Holen Sie sich die Stockscreener-App
243.87
0.21%
-0.52
Vorhandelsmarkt:
242.22
-1.65
-0.68%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$244.39
Offen:
$243.97
24-Stunden-Volumen:
837.68K
Relative Volume:
0.92
Marktkapitalisierung:
$26.92B
Einnahmen:
$11.28B
Nettoeinkommen (Verlust:
$1.07B
KGV:
26.90
EPS:
9.0657
Netto-Cashflow:
$1.33B
1W Leistung:
+3.55%
1M Leistung:
+7.03%
6M Leistung:
+16.38%
1J Leistung:
+35.31%
1-Tages-Spanne:
$242.46
$246.00
1-Wochen-Bereich:
$236.07
$246.00
52-Wochen-Spanne:
$171.18
$246.00
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, NTRA, IDXX, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
243.87 | 26.63B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
628.74 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.11 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
327.72 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
IDXX
Idexx Laboratories Inc
|
559.51 | 43.00B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
153.43 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Quest Diagnostics stock holds near highs after Q2 beat - Ad-hoc-news.de
Is it the Right Time to Retain DGX Stock in Your Portfolio? - TradingView
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Trillium Asset Management LLC Takes $5.43 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
SGL Investment Advisors Inc. Buys Shares of 27,290 Quest Diagnostics Incorporated $DGX - MarketBeat
Danske Bank A S Buys Shares of 68,561 Quest Diagnostics Incorporated $DGX - MarketBeat
5,500 Shares in Quest Diagnostics Incorporated $DGX Acquired by Glaxis Capital Management LLC - MarketBeat
Edmond DE Rothschild Holding S.A. Invests $944,000 in Quest Diagnostics Incorporated $DGX - MarketBeat
Ceredex Value Advisors LLC Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
327,575 Shares in Quest Diagnostics Incorporated $DGX Bought by Advisors Capital Management LLC - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Quest Diagnostics stock extends 2026 rally after Q2 revenue and earnings beat - Ad-hoc-news.de
Tocqueville Asset Management L.P. Takes $22.67 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Wealthfront Advisers LLC Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Deutsche Bank AG Makes New $124.18 Million Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
BlackRock Inc. Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics stock hits a fresh high as Q2 earnings beat expectations - Ad-hoc-news.de
Quest Diagnostics stock hits all-time high at 240.15 USD - Investing.com
Quest Diagnostics stock hits all-time high at 240.15 USD By Investing.com - Investing.com Canada
M.D. Sass LLC Buys New Shares in Quest Diagnostics Incorporated $DGX - MarketBeat
Commerzbank Aktiengesellschaft FI Takes $1.42 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Foster & Motley Inc. Makes New $3.51 Million Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Danica Pension Livsforsikringsaktieselskab Invests $2.26 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
Alpine Woods Capital Investors LLC Acquires New Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why - Yahoo Finance
WHOOP opens blood tests to nonmembers and adds a test for signals tied to 50+ cancer types - Stock Titan
Nuance Investments LLC Takes Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Occidental Asset Management LLC Invests $6.12 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
Cornerstone Advisors LLC Invests $10.01 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
GSA Capital Partners LLP Purchases Shares of 4,971 Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (NYSE:DGX) Shows Dividend Quality Beyond the Headline Yield - ChartMill
Simplicity Wealth LLC Acquires New Position in Quest Diagnostics Incorporated $DGX - MarketBeat
J.Safra Asset Management Corp Purchases New Shares in Quest Diagnostics Incorporated $DGX - MarketBeat
ABN AMRO Bank N.V. Takes $21.52 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Carol Devine Miller sells stocks in Pfizer, Quest Diagnostics, Target, and U.S. Bancorp - Investing.com South Africa
Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know - Yahoo Finance
T. Rowe Price Associates (DGX) discloses 5.43M Quest Diagnostics shares in 13G/A - Stock Titan
Assenagon Asset Management S.A. Acquires 4,334 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Plans Quarterly Dividend of $0.86 - MarketBeat
Quest Diagnostics Inc (DGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Q2 2026 Quest Diagnostics Inc Earnings Call Transcript - GuruFocus
Rep. Carol Miller's household sold Pfizer, Quest, Target, and U.S. Bancorp 521 days before disclosure - 24/7 Wall St.
Quest Diagnostics Keeps Quarterly Dividend at $0.86 per Share, Payable Oct. 21, to Shareholders of Record Oct. 6 - marketscreener.com
Quest Diagnostics Declares Quarterly Cash Dividend - marketscreener.com
Quest Diagnostics Sets Oct. 21 Date for Cash Dividend - Stock Titan
Diversified Management Inc. Lowers Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
IVY LANE CAPITAL MANAGEMENT, LLC's Quest Diagnostics Inc(DGX) Holding History - GuruFocus
Quest Diagnostics Incorporated $DGX Holdings Trimmed by Empowered Funds LLC - MarketBeat
Quest Diagnostics Inc (DGX) Stock News Today - TradingKey
Quest Diagnostics Inc (DGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.89%
3.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):